Literature DB >> 33188913

Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation.

Jacob Sands1, Martin C Tammemägi2, Sebastien Couraud3, David R Baldwin4, Andrea Borondy-Kitts5, David Yankelevitz6, Jennifer Lewis7, Fred Grannis8, Hans-Ulrich Kauczor9, Oyunbileg von Stackelberg9, Lecia Sequist10, Ugo Pastorino11, Brady McKee12.   

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for almost a fifth of all cancer-related deaths. Annual computed tomographic lung cancer screening (CTLS) detects lung cancer at earlier stages and reduces lung cancer-related mortality among high-risk individuals. Many medical organizations, including the U.S. Preventive Services Task Force, recommend annual CTLS in high-risk populations. However, fewer than 5% of individuals worldwide at high risk for lung cancer have undergone screening. In large part, this is owing to delayed implementation of CTLS in many countries throughout the world. Factors contributing to low uptake in countries with longstanding CTLS endorsement, such as the United States, include lack of patient and clinician awareness of current recommendations in favor of CTLS and clinician concerns about CTLS-related radiation exposure, false-positive results, overdiagnosis, and cost. This review of the literature serves to address these concerns by evaluating the potential risks and benefits of CTLS. Review of key components of a lung screening program, along with an updated shared decision aid, provides guidance for program development and optimization. Review of studies evaluating the population considered "high-risk" is included as this may affect future guidelines within the United States and other countries considering lung screening implementation.
Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CTLS; LDCT; Lung cancer screening; low-dose CT

Mesh:

Year:  2020        PMID: 33188913     DOI: 10.1016/j.jtho.2020.10.127

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  15 in total

1.  Pathologic and gene expression comparison of CT- screen detected and routinely detected stage I/0 lung adenocarcinoma in NCCN risk-matched cohorts.

Authors:  Eric J Burks; Jiarui Zhang; Travis B Sullivan; Xingyi Shi; Jacob M Sands; Shawn M Regis; Brady J McKee; Andrea B McKee; Sherry Zhang; Hanqiao Liu; Gang Liu; Avrum Spira; Jennifer Beane; Marc E Lenburg; Kimberly M Rieger-Christ
Journal:  Cancer Treat Res Commun       Date:  2021-11-10

2.  Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer.

Authors:  Jelena Spasic; Milena Cavic; Nemanja Stanic; Bojan Zaric; Tomi Kovacevic; Davorin Radosavljevic; Ljudmila Nagorni-Obradovic
Journal:  Dose Response       Date:  2022-06-28       Impact factor: 2.623

3.  TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.

Authors:  Shuai Zhang; Mengru Cao; Shi Yan; Yuechao Liu; Weina Fan; Yimeng Cui; Fanglin Tian; Ruixue Gu; Yaowen Cui; Yuning Zhan; Yuanyuan Sun; Ying Xing; Li Cai; Yang Song
Journal:  Int J Biol Sci       Date:  2022-04-18       Impact factor: 10.750

Review 4.  Implementing Lung Cancer Screening in Europe: Taking a Systems Approach.

Authors:  Suzanne Wait; Arturo Alvarez-Rosete; Tasnime Osama; Dani Bancroft; Robin Cornelissen; Ante Marušić; Pilar Garrido; Mariusz Adamek; Jan van Meerbeeck; Annemiek Snoeckx; Olivier Leleu; Ebba Hallersjö Hult; Sébastien Couraud; David R Baldwin
Journal:  JTO Clin Res Rep       Date:  2022-04-22

5.  CT-Assisted Improvements in the Accuracy of the Intraoperative Frozen Section Examination of Ground-Glass Density Nodules.

Authors:  Wang Xinli; Sun Xiaoshuang; Yan Chengxin; Zhang Qiang
Journal:  Comput Math Methods Med       Date:  2022-01-07       Impact factor: 2.238

6.  Improving lung cancer screening: An equitable strategy through a tobacco treatment clinic.

Authors:  Panagis Galiatsatos; Raiza Schreiber; Kamala Green; Rohan Shah; Hans Lee; David Feller-Kopman; Lonny Yarmus; Jeffrey Thiboutot; Cheng Ting Lin; Norma Kanarek
Journal:  Prev Med Rep       Date:  2021-09-17

7.  Gene expression and prognosis of x-ray repair cross-complementing family members in non-small cell lung cancer.

Authors:  Yongfei Fan; Zhaojia Gao; Xinwei Li; Shuzhang Wei; Kai Yuan
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Circular RNA Circ_0000677 promotes cell proliferation by regulating microRNA-106b-5p/CCND1 in non-small cell lung cancer.

Authors:  Xin Hu; Ping Wang; Chen Qu; Haibo Zhang; Liang Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 9.  Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer.

Authors:  Xu Lin; Jiahe Wu; Yupeng Liu; Nengming Lin; Jian Hu; Bo Zhang
Journal:  Molecules       Date:  2022-01-30       Impact factor: 4.411

Review 10.  Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.

Authors:  Shengjie Tang; Chao Qin; Haiyang Hu; Tao Liu; Yiwei He; Haiyang Guo; Hang Yan; Jun Zhang; Shoujun Tang; Haining Zhou
Journal:  Cells       Date:  2022-01-19       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.